ProQR Therapeutics N.V. PRQR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.39M | 15.54M | 17.91M | 17.05M | 17.90M |
| Total Other Revenue | 71.20K | 250.50K | 484.10K | 596.50K | 709.60K |
| Total Revenue | 21.46M | 15.79M | 18.40M | 17.64M | 18.61M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 21.46M | 15.79M | 18.40M | 17.64M | 18.61M |
| SG&A Expenses | 18.40M | 18.15M | 17.05M | 16.69M | 16.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.48M | 69.44M | 67.46M | 66.87M | 64.23M |
| Operating Income | -50.01M | -53.65M | -49.07M | -49.22M | -45.61M |
| Income Before Tax | -49.03M | -52.71M | -47.66M | -47.19M | -43.24M |
| Income Tax Expenses | 30.30K | 21.60K | 21.60K | 20.40K | 20.40K |
| Earnings from Continuing Operations | -49.06 | -52.73 | -47.68 | -47.22 | -43.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.06M | -52.73M | -47.68M | -47.22M | -43.26M |
| EBIT | -50.01M | -53.65M | -49.07M | -49.22M | -45.61M |
| EBITDA | -47.33M | -51.03M | -46.54M | -46.72M | -43.14M |
| EPS Basic | -0.46 | -0.50 | -0.45 | -0.45 | -0.44 |
| Normalized Basic EPS | -0.29 | -0.31 | -0.28 | -0.28 | -0.28 |
| EPS Diluted | -0.47 | -0.51 | -0.46 | -0.46 | -0.45 |
| Normalized Diluted EPS | -0.29 | -0.31 | -0.28 | -0.28 | -0.28 |
| Average Basic Shares Outstanding | 426.02M | 421.40M | 421.34M | 415.41M | 391.75M |
| Average Diluted Shares Outstanding | 426.02M | 421.40M | 421.34M | 415.41M | 391.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |